Key Takeaways
- • Chemify raised more than $50 million in an oversubscribed Series B round co-led by Wing Venture Capital and Insight Partners, according to a Business Wire announcement dated October 21, 2025.
- • Participating investors include 8VC and existing backers Triatomic Capital, Blueyard, Rockspring and Eos.
- • The capital will scale Chemify's Chemputation platform and its Chemifarm facilities, with plans to build a network of digital chemistry hubs and a Silicon Valley facility led by CTO Mike Bell.
- • Ansuman Satpathy (Wing Venture Capital) and Aiden Aceves (Insight Partners) have joined Chemify's Board of Directors in conjunction with the financing.
- • Chemify, a Glasgow-headquartered spin-out from the University of Glasgow founded in 2022, targets on-demand molecule design and manufacturing for pharmaceutical, biotech and materials-science partners.
Summary
Chemify, a deep-tech company combining chemistry, robotics, computation and its proprietary Chemputation AI platform, has raised more than $50 million in Series B funding, according to a Business Wire announcement. The round was co-led by Wing Venture Capital and Insight Partners and drew participation from 8VC, along with existing backers Triatomic Capital, Blueyard, Rockspring and Eos. The company described the round as oversubscribed.
The financing is intended to scale Chemify's Chemputation platform and its Chemifarm facilities. Earlier this year, Chemify launched its first Chemifarm, a fully automated chemistry facility designed to be a leading laboratory for molecular design and synthesis. The facility integrates the Chemputation platform, an extensible programming language, advanced robotics and what the company describes as the world's largest curated library of validated reactions. The Series B proceeds will support a network of digital chemistry hubs and on-demand molecule design and manufacturing for pharmaceutical, biotech and materials-science partners. Chemify also plans to open a Silicon Valley facility led by Chief Technical Officer Mike Bell.
CEO and founder Lee Cronin said the company aims to become the global digital backbone of chemistry, with the ability to design and make any molecule on demand across applications from drug discovery to new catalysts and electronic materials. Ansuman Satpathy, Partner at Wing Venture Capital, said Chemify's technology uses automation and physical AI to make chemical synthesis programmable. Aiden Aceves, Vice President at Insight Partners, said Chemify's use of AI to ensure the makeability of complex molecules represents a paradigm shift in medicinal chemistry, citing strong results from early pharma collaborations. Satpathy and Aceves have both joined Chemify's Board of Directors.
Founded in 2022 as a spin-out from the University of Glasgow and headquartered in Glasgow, Scotland, Chemify is positioned at the intersection of automation, AI and data for drug and advanced materials discovery. The announcement did not disclose a valuation or the full investor breakdown beyond the named participants.
The financing is intended to scale Chemify's Chemputation platform and its Chemifarm facilities. Earlier this year, Chemify launched its first Chemifarm, a fully automated chemistry facility designed to be a leading laboratory for molecular design and synthesis. The facility integrates the Chemputation platform, an extensible programming language, advanced robotics and what the company describes as the world's largest curated library of validated reactions. The Series B proceeds will support a network of digital chemistry hubs and on-demand molecule design and manufacturing for pharmaceutical, biotech and materials-science partners. Chemify also plans to open a Silicon Valley facility led by Chief Technical Officer Mike Bell.
CEO and founder Lee Cronin said the company aims to become the global digital backbone of chemistry, with the ability to design and make any molecule on demand across applications from drug discovery to new catalysts and electronic materials. Ansuman Satpathy, Partner at Wing Venture Capital, said Chemify's technology uses automation and physical AI to make chemical synthesis programmable. Aiden Aceves, Vice President at Insight Partners, said Chemify's use of AI to ensure the makeability of complex molecules represents a paradigm shift in medicinal chemistry, citing strong results from early pharma collaborations. Satpathy and Aceves have both joined Chemify's Board of Directors.
Founded in 2022 as a spin-out from the University of Glasgow and headquartered in Glasgow, Scotland, Chemify is positioned at the intersection of automation, AI and data for drug and advanced materials discovery. The announcement did not disclose a valuation or the full investor breakdown beyond the named participants.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.